Thomas M. Habermann

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.1Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Papers

Driven by 49 papers — median percentile 90. Top paper: “The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes”.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

Blood(2008)10.1182/blood-2007-07-100115

N/A

0.862DataRank · unranked

312 citations

Stefano Monti, Przemyslaw Juszczynski, John Daley, Wen Chen, Thomas E. Witzig +4 more

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1345

N/A

0.851DataRank · unranked

22 citations

Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig +11 more

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma

Blood Cancer Journal(2021)10.1038/s41408-021-00521-4

N/A

0.631DataRank · unranked

66 citations

Angelo Famà, Melissa C. Larson, Andrew L. Feldman, José C. Villasboas, Zhi-Zhang Yang +20 more

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

Leukemia(2022)10.1038/s41375-022-01711-0

N/A

0.529DataRank · unranked

33 citations

Vijai Joseph, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang +95 more

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

Blood Cancer Journal(2020)10.1038/s41408-020-00382-3

N/A

0.520DataRank · unranked

31 citations

Kerstin Wenzl, Keenan T. Hartert, Michelle K. Manske, Vivekananda Sarangi, Matthew J. Maurer +10 more

Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma

American Journal of Hematology(2022)10.1002/ajh.26715

N/A

0.494DataRank · unranked

26 citations

Isildinha M. Reis, Thomas M. Habermann, Brian K. Link, Catherine Thiéblemont, Annarita Conconi +7 more

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study

American Journal of Hematology(2025)10.1002/ajh.27630

N/A

0.409DataRank · unranked

10 citations

Jean L. Koff, Melissa C. Larson, Brad S. Kahl, Carla Casulo, Izidore S. Lossos +25 more

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL

Blood Cancer Journal(2024)10.1038/s41408-024-01080-0

N/A

0.385DataRank · unranked

12 citations

Matthew E. Stokes, Joseph P. Novak, Allison M. Bock, Sana Khan, Melissa A. Hopper +25 more

Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101443

N/A

0.373DataRank · unranked

11 citations

Kerstin Wenzl, Melissa A. Hopper, Michelle K. Manske, Vivekananda Sarangi, Matthew J. Maurer +16 more

Genetically Determined Height and Risk of Non-hodgkin Lymphoma

Frontiers in Oncology(2020)10.3389/fonc.2019.01539

N/A

0.345DataRank · unranked

9 citations

Eleanor Kane, Zhaoming Wang, Orestis A. Panagiotou, Lauren R. Teras, Alain Monnereau +74 more

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood(2024)10.1182/blood.2024025681

N/A

0.269DataRank · unranked

5 citations

Matthew J. Maurer, Thomas M. Habermann, Richard Burack, Jennifer R. Chapman, Jonathon B. Cohen +18 more

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Blood(2016)10.1182/blood.v128.22.4196.4196

N/A

0.208DataRank · unranked

3 citations

Norbert Schmitz, Christopher Flowers, Fang-Shu Ou, David Cunningham, Michael Pfreundschuh +14 more

Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7573

N/A

0.104DataRank · unranked

1 citations

Melissa C. Larson, Jonathan R Day, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +15 more

Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8052

N/A

0.104DataRank · unranked

1 citations

Angelo Famà, Melissa C. Larson, Andew L. Feldman, Zhi-Zhang Yang, José C. Villasboas +13 more

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2022009225

N/A

0DataRank · unranked

11 citations

Jeffrey M. Switchenko, Veronika Bachanová, James N. Gerson, Stefan K. Barta, Max J. Gordon +30 more

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Blood Cancer Journal(2023)10.1038/s41408-023-00942-3

N/A

0DataRank · unranked

9 citations

Jennifer Gile, Melissa C. Larson, Kittika Poonsombudlert, Reema Tawfiq, Seth Maliske +14 more

Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab

British Journal of Haematology(2023)10.1111/bjh.19153

N/A

0DataRank · unranked

5 citations

Allison Rosenthal, Ryan S. Robetorye, Raphael Mwangi, Matthew J. Maurer, Diego Villa +20 more

Molecular classification and identification of an aggressive signature in low‐grade B‐cell lymphomas

Hematological Oncology(2023)10.1002/hon.3187

N/A

0DataRank · unranked

5 citations

Kerstin Wenzl, Keenan T. Hartert, Jordan E. Krull, Abigail R. Dropik, Joseph P. Novak +16 more

Data from Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma

(2023)10.1158/1055-9965.c.6516286.v1

N/A

0DataRank · unranked

0 citations

Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan +8 more

Defining primary refractory large B-cell lymphoma

Blood Advances(2024)10.1182/bloodadvances.2024012760

N/A

0DataRank · unranked

32 citations

Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers +15 more

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

Nature Communications(2024)10.1038/s41467-024-50830-y

N/A

0DataRank · unranked

17 citations

Kerstin Wenzl, C. Chris Huang, María Ortiz, Chih-Chao Hsu, Matthew J. Maurer +23 more

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102592

N/A

0DataRank · unranked

14 citations

Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli +30 more

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance

Hematological Oncology(2024)10.1002/hon.70006

N/A

0DataRank · unranked

2 citations

Kerstin Wenzl, Joseph P. Novak, Matthew E. Stokes, Melissa A. Hopper, Jordan E. Krull +17 more

DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas

Blood Cancer Journal(2024)10.1038/s41408-024-01145-0

N/A

0DataRank · unranked

4 citations

Abigail R. Dropik, Janek S. Walker, Joseph P. Novak, M. Laverty, Michelle K. Manske +16 more

Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes

UNC Libraries(2024)10.17615/e1wv-7413

N/A

0DataRank · unranked

0 citations

Sílvia de Sanjosé, Ruth C. Travis, Paul Brennan, Michael Dean, Weiyin Zhou +77 more

Transformation of marginal zone lymphoma to Hodgkin lymphoma

UNC Libraries(2024)10.17615/qw81-3587

N/A

0DataRank · unranked

0 citations

Juan Pablo Alderuccio, James R. Cerhan, Kamilia Moalem, Brian K. Link, Izidore S. Lossos +3 more

Risk of lymphoid malignancy associated with cancer predisposition genes

Blood Cancer Journal(2025)10.1038/s41408-025-01283-z

N/A

0DataRank · unranked

8 citations

Raphael Mwangi, Dennis P. Robinson, Cristine Allmer, Allison Rosenthal, Thomas M. Habermann +95 more

Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma

Blood Cancer Journal(2025)10.1038/s41408-025-01326-5

N/A

0DataRank · unranked

7 citations

Kerstin Wenzl, Joseph P. Novak, Matthew E. Stokes, Melissa A. Hopper, Abigail R. Dropik +17 more

Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series

The Lancet Haematology(2025)10.1016/s2352-3026(25)00027-4

N/A

0DataRank · unranked

4 citations

Ajay Major, Vishal Bhatnagar, Amylou C. Dueck, Karin E. Smedby, Tarec Christoffer El‐Galaly +8 more

Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin

Cancer Epidemiology Biomarkers & Prevention(2025)10.1158/1055-9965.epi-24-1610

N/A

0DataRank · unranked

0 citations

Dennis P. Robinson, Lisa M. Rimsza, Melissa C. Larson, Rebecca L. King, Grzegorz S. Nowakowski +9 more

29 | A COMPARATIVE ANALYSIS OF HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA AT DIAGNOSIS (COMPOSITE LYMPHOMA) AND SEQUENTIALLY TRANSFORMED FOLLICULAR LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70093_29

N/A

0DataRank · unranked

0 citations

Melissa C. Larson, Jonathan Day, Urshila Durani, Mazie Tsang, Dai Chihara +22 more

Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses

International Journal of Cancer(2025)10.1002/ijc.70039

N/A

0DataRank · unranked

0 citations

Eleanor Kane, Lauren R. Teras, Mitchell J. Machiela, Joshua Arias, Orestis A. Panagiotou +70 more

Meta-analysis of genome-wide association studies of doxorubicin-induced arrhythmia identifies MMP16 and KCTD15 as risk loci

medRxiv(2025)10.64898/2025.12.16.25342433

N/A

0DataRank · unranked

0 citations

Milagros Pereyra, Mohammed Tiseer Abbas, Reza Arsanjani, Isaac Prah, Nicholas Boddicker +16 more

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00892

N/A

0DataRank · unranked

1 citations

Vít Procházka, Tarec Christoffer El‐Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy +43 more

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30067-3

N/A

0DataRank · unranked

29 citations

John P. Leonard, Thomas E. Witzig, Thomas M. Habermann, Kristie A. Blum, Nancy L. Bartlett +8 more

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

British Journal of Haematology(2020)10.1111/bjh.16425

N/A

0DataRank · unranked

23 citations

Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob Haaber Christensen, Judit Jørgensen +19 more

Testicular FDG‐PET/CT uptake threshold in aggressive lymphomas

American Journal of Hematology(2020)10.1002/ajh.26073

N/A

0DataRank · unranked

4 citations

Hidong Kim, Laura Harper, Thomas M. Habermann, Grzegorz S. Nowakowski, Carrie A. Thompson +8 more

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

UNC Libraries(2020)10.17615/y5gv-3561

N/A

0DataRank · unranked

0 citations

Anneclaire J. De Roos, Brian K. Link, Anne J. Novak, Yuanqing Ye, Mitchell J. Machiela +95 more

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

American Journal of Hematology(2021)10.1002/ajh.26230

N/A

0DataRank · unranked

24 citations

Melissa C. Larson, Alessia Castellino, Joerg Herrmann, David J. Inwards, Gita Thanarajasingam +10 more

Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma

American Journal of Hematology(2021)10.1002/ajh.26149

N/A

0DataRank · unranked

22 citations

Lasse Hjort Jakobsen, Raphael Mwangi, Norbert Schmitz, Umar Farooq, C. R. Flowers +18 more

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

Blood Cancer Journal(2021)10.1038/s41408-020-00394-z

N/A

0DataRank · unranked

17 citations

Aung M. Tun, Yucai Wang, Thomas M. Habermann, Rebecca L. King, Kay M. Ristow +7 more

How I treat cardiovascular complications in patients with lymphoid malignancies

Blood(2021)10.1182/blood.2019003893

N/A

0DataRank · unranked

9 citations

Kristen McCullough, Thomas M. Habermann, Joerg Herrmann

Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1941931

N/A

0DataRank · unranked

7 citations

Kristin C. Mara, Erin F. Barreto, Nelson Leung, Thomas M. Habermann, Heather P. May

Vaccination History and Risk of Lymphoma and Its Major Subtypes

Cancer Epidemiology Biomarkers & Prevention(2021)10.1158/1055-9965.epi-21-0383

N/A

0DataRank · unranked

4 citations

Melissa C. Larson, Stephen M. Ansell, Carrie A. Thompson, Grzegorz S. Nowakowski, Timothy G. Call +10 more

Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma

International Journal of Cancer(2021)10.1002/ijc.33541

N/A

0DataRank · unranked

8 citations

Melissa C. Larson, Carrie A. Thompson, Grzegorz S. Nowakowski, Timothy G. Call, William R. Macon +5 more

Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes

Journal of Translational Genetics and Genomics(2021)10.20517/jtgg.2021.08

N/A

0DataRank · unranked

0 citations

Mitchell J. Machiela, Moara Machado, Sophia Wang, Eleanor Kane, Susan L. Slager +77 more

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

The Lancet Haematology(2022)10.1016/s2352-3026(22)00033-3

N/A

0DataRank · unranked

64 citations

Melissa C. Larson, Julianne J. Lunde, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +19 more

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Hematological Oncology(2022)10.1002/hon.3098

N/A

0DataRank · unranked

7 citations

Raphael Mwangi, Alexandra N. Smith, Matthew J. Maurer, Umar Farooq, Rebecca L. King +9 more

Thomas M. Habermann

Indexed papers

Top data-sharing exemplar

Papers